Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Univariate and multivariate analysis of clinicopathological factors with serum osteopontin level (A), serum thrombospondin-1 level (B), serum OPN/TSP-1 ratio (C) for distant metastasis-free survival (DMFS)

From: Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer

   Univariate analysis Multivariate analysis
   HR 95 % CI p value HR 95 % CI p value
A. Factors associated with serum osteopontin level for distant metastasis-free survival
Osteopontin Serum levela 1.69 1.12–2.56 0.01 1.35 0.93–1.97 0.12
Stage I to IIIA vs IIIB 0.23 0.12–0.44 <0.0001 0.31 0.15–0.63 0.001
Pleural involvement Positive vs Negative 2.58 1.50–4.43 <0.001 1.91 1.07–3.40 0.03
Lympho-vascular invasion Positive vs Negative 2.33 1.37–3.87 0.002 1.80 1.02–3.17 0.04
Adjuvant treatment No vs Yes 1.20 0.70–2.04 0.54
Age ≥65 vs <65 1.05 0.56–1.97 0.91
Gender Male vs female 0.97 0.59–1.61 0.92
Smoking history Smoker vs non-smoker 1 0.51–1.97 1
B. Factors associated with serum thrombospondin-1 level for distant metastasis-free survival
Thrombospondin-1 Serum levelb 0.39 0.10–1.45 0.23
Stage I to IIIA vs IIIB 0.23 0.12–0.44 <0.0001 0.29 0.14–0.58 0.001
Pleural involvement Positive vs Negative 2.58 1.50–4.43 <0.001 1.91 1.07–3.41 0.03
Lympho-vascular invasion Positive vs Negative 2.33 1.37–3.87 0.002 1.79 1.01–3.14 0.04
Adjuvant treatment No vs Yes 1.20 0.70–2.04 0.54
Age ≥65 vs <65 1.05 0.56–1.97 0.91
Gender Male vs female 0.97 0.59–1.61 0.92
Smoking history Smoker vs non-smoker 1 0.51–1.97 1
C. Factors associated with serum osteopontin/thrombospondin-1 ratio for distant metastasis-free survival
OPN/TSP1 Ratioc 1.31 1.06–1.59 0.01 1.16 0.97–1.40 0.11
Stage I to IIIA vs IIIB 0.23 0.12–0.44 <0.0001 0.31 0.15–0.63 0.001
Pleural involvement Positive vs Negative 2.58 1.50–4.43 <0.001 1.90 1.07–3.40 0.03
Lympho-vascular invasion Positive vs Negative 2.33 1.37–3.87 0.002 1.80 1.02–3.17 0.04
Adjuvant treatment No vs Yes 1.20 0.70–2.04 0.54
Age ≥65 vs <65 1.05 0.56–1.97 0.91
Gender Male vs female 0.97 0.59–1.61 0.92
Smoking history Smoker vs non-smoker 1 0.51–1.97 1
  1. HR Hazard Ratio, 95 % CI 95 % Confidence interval
  2. afor an increment in OPN of 50 ng/mL
  3. bfor an increment in TSP-1 of 10 ng/mL in log10 scale
  4. cfor an increment of 6 ng/mL in the ratio OPN/log10 (TSP1)